UNSPSC 51384300: Nonsteroidal anti inflammatory piperidines

Nonsteroidal anti inflammatory drugs made from a family of hexahydropyridines.

UNSPSC 51384300 Nonsteroidal anti inflammatory piperidines is a Class code that captures pharmaceutical products, though recent state and local procurement activity under this code shows a broader scope including naloxone, generic multi-source pharmaceuticals, and over-the-counter products rather than nonsteroidal anti-inflammatory agents alone. State and local issuing bodies soliciting under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Seminole County, Florida, for example, recently issued an invitation for bid for naloxone and drug deactivation systems to support community health initiatives, while the Texas Health and Human Services Commission posted a request for information to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers a broader RFP for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in multiple states including Oregon.

Geographic activity centers on Florida, Texas, and Minnesota, with MMCAP's multi-state cooperative purchasing structure extending reach across additional jurisdictions. The Seminole County naloxone procurement (IFB 60459723LAS, due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, electronic bidding through the county e-procurement portal, and a two-year initial term with one-year renewal option; vendors must meet E-Verify, drug-free workplace, and insurance requirements including workers' compensation and commercial general liability coverage. The MMCAP RFP (S1070000015802, due March 26, 2026) establishes multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awards effective July 1, 2026; vendors must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two of three wholesalers, and carry commercial general liability coverage of $5,000,000 per occurrence. The Texas HHS RFI (HHS0017013, posted April 3, 2026) represents preliminary market intelligence gathering for direct-to-manufacturer prescription contracting rather than a formal competitive solicitation.